Rifampin

Rifampin · RIFAMPIN 600 mg/1 · Injection, Powder, Lyophilized, For Solution · Intravenous · Fresenius Kabi USA, LLC

NDC 63323-0351-20 · 1 VIAL in 1 BOX / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL · ANDA · View full market →

The short version

4 companies supply this market — a reasonable cushion if one runs into trouble. It is in shortage right now — FDA lists the reason as “discontinuation of the manufacture of the drug”.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built

Data sources

CMS NADAC (pharmacy acquisition, weekly)
CMS Part B ASP quarterly payment limits
CMS Maximum Fair Prices (IRA negotiated, NDC-level)
Medicare Part D Spending by Drug (data.cms.gov, name-matched)
VA FSS / Big4 federal contract prices (va.gov, twice monthly)
ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
California SB-17 WAC filings (list price, per package)

Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Medicare Part B pays (ASP+6%)$0.1720per billing unit (1 MG)HCPCS J2804 · Jul 1, 2026
Part D plans paid (avg)$0.9842per dosage unitgross, before rebates — matched by drug name · 2024
Federal contracts pay (FSS)$93.04per package of 20MLFresenius Kabi, LLC · May 15, 2025

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed

$153.00

Reported to Texas DSHS · 2026 annual filing · Fresenius Kabi USA

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 1 MG

$0.172

HCPCS J2804 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$8,425

44 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Where it's made

Fresenius Kabi USA, LLCUnited States
analysis · manufacture

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

Part D specialty tier
Costs ≥ $950/fill · avg $61.54 per prescription
Biologic (BLA)
Injectable / infused
Orphan-drug exclusivity
REMS program

Regulatory

Application: ANDA091181
TE code: AP
Approval date: Aug 21, 2014
Patents / exclusivity: None on file

Shortage history

In shortage now — Rifadin, Injection, 600 mg (NDC 0068-0597-01)Feb 17, 2021
Discontinuation of the manufacture of the drug
month 67 — 3× the typical 20-month injectable shortage · model puts 14% odds it resolves within 6 months
Planned discontinuation — Rifadin, Injection, 600 mg/10 mL (NDC 0068-0597-01)Feb 17, 2021
In shortage now — Rifampin, Injection, 600 mg (NDC 63323-351-20)Feb 17, 2021
month 67 — 3× the typical 20-month injectable shortage · model puts 14% odds it resolves within 6 months
In shortage now — Rifampin, Injection, 600 mg (NDC 67457-445-60)Feb 17, 2021
Demand increase for the drug
month 67 — 3× the typical 20-month injectable shortage · model puts 14% odds it resolves within 6 months
In shortage now — Rifampin, Injection, 600 mg/10 mL (NDC 67457-445-60)Feb 17, 2021
Demand increase for the drug
month 67 — 3× the typical 20-month injectable shortage · model puts 14% odds it resolves within 6 months

Recalls (this NDC)

Class II · TerminatedJun 4, 2015
Fresenius Kabi USA, LLC — Failed Impurities/Degradation Specifications; out-of-specification for color, impurity, and degradation

Manufacturers of Rifampin (Injection, Powder, Lyophilized, For Solution)

Labeler	Strength	First seen	Last seen
Fresenius Kabi USA, LLC	RIFAMPIN 600 mg/1	Jul 15, 2026	Sep 2, 2026
Hikma Pharmaceuticals USA Inc.	RIFAMPIN 600 mg/1	Jul 15, 2026	Sep 2, 2026
Mylan Institutional LLC	RIFAMPIN 600 mg/10mL	Jul 15, 2026	Sep 2, 2026
Sanofi-Aventis U.S. LLC	RIFAMPIN 600 mg/10mL	Jul 15, 2026	Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Rifampin — NDC 63323-0351-20," retrieved September 3, 2026, https://drugdashboards.com/drug/63323035120.

Free to cite with attribution — see how the data is put together.